CIR and 95% CI stratified by pretransplantation HCMV serostatus and post-transplantation HCMV pp65-antigenemia. (A) CIR by pretransplantation HCMV serostatus of donors and recipients (P < .0001). (B) CIR by post-transplantation pp65-antigenemia (P < .0001). (C) CIR by post-transplantation pp65-antigenemia of patients surviving free of relapse at day 100 after transplantation (P < .0001). Tick marks indicate patients surviving free of relapse or competing events.